

30.01.2021

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 524669

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra - Kurla Complex,
Bandra (E), Mumbai - 400 051

Symbol: HESTERBIO

Respected Sir / Madam:

Subject: Outcome of Board Meeting

This is with reference to our letter dated 21.01.2021 intimating the date of the Board Meeting for consideration of the Standalone and Consolidated Unaudited Financial Results for the quarter and nine months ended on 31.12.2020.

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors, in their Meeting held today, have approved the followings:

1. Standalone and Consolidated Unaudited Financial Results for the quarter and nine months ended on 31.12.2020.
2. Issuance of equity shares, and/or equity linked securities and/or securities convertible into equity shares through Qualified Institutional Placement (QIP) or preferential allotment for an amount not exceeding INR 200 crores, subject to approval of members through Postal Ballot process.

We attach herewith:

1. The approved Standalone and Consolidated Unaudited Financial Results and Limited Review Reports.
2. Press Release issued in this regard

We would be publishing the extract of results in the newspaper as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 10:40 a.m. and concluded at 11:00 a.m.

You are requested to take the above information on your record.

Sincerely,
For Hester Biosciences Limited


Rajiv Gandhi
CEO & Managing Director
DIN: 00438037